Sara Nik
Stock Analyst at H.C. Wainwright
(0.57)
# 4,074
Out of 4,491 analysts
44
Total ratings
22.7%
Success rate
-5.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sara Nik
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVRD Tvardi Therapeutics | Maintained: Buy | $9 | $4.72 | +90.68% | 2 | Jul 7, 2026 | |
| STO: CANTA Cantargia AB (publ) | Reiterated: Buy | kr 14.00 | $2.00 | +600.00% | 9 | Jul 2, 2026 | |
| MBRX Moleculin Biotech | Reiterated: Buy | $22 | $2.33 | +846.24% | 16 | Jul 1, 2026 | |
| KTTA Pasithea Therapeutics | Reiterated: Buy | $3 | $0.5036 | +495.71% | 8 | Jul 1, 2026 | |
| CRIS Curis | Reiterated: Buy | $17 | $4.81 | +253.25% | 8 | Jun 26, 2026 | |
| KAPA Kairos Pharma | Reiterated: Buy | $12 | $0.3792 | +3,064.56% | 1 | Aug 13, 2025 |
Tvardi Therapeutics
Jul 7, 2026
Maintained: Buy
Price Target: $9
Current: $4.72
Upside: +90.68%
Cantargia AB (publ)
Jul 2, 2026
Reiterated: Buy
Price Target: kr 14.00
Current: $2.00
Upside: +600.00%
Moleculin Biotech
Jul 1, 2026
Reiterated: Buy
Price Target: $22
Current: $2.33
Upside: +846.24%
Pasithea Therapeutics
Jul 1, 2026
Reiterated: Buy
Price Target: $3
Current: $0.5036
Upside: +495.71%
Curis
Jun 26, 2026
Reiterated: Buy
Price Target: $17
Current: $4.81
Upside: +253.25%
Kairos Pharma
Aug 13, 2025
Reiterated: Buy
Price Target: $12
Current: $0.3792
Upside: +3,064.56%